A Single and Multiple Ascending Dose Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of KP-1199

Exclusion Criteria

• •Women who are pregnant, lactating, or planning to attempt to become pregnant during this study or within 90 days after the follow-up visit.
• •Males with female partners who are planning to attempt to become pregnant during this study or within 90 days after the follow-up visit.
• •History or evidence of significant clinical or psychiatric disorder, condition, or disease that, in the opinion of the Investigator would pose an unacceptable risk to the subject safety or interfere with the study evaluations, procedures, or completion of the study.
• •Documented congenital QT syndrome, and/or corrected QT interval (Fridericia correction; QTcF) at screening or first admission \> 450 ms.
• •Positive screening test for hepatitis B surface antigen, anti-hepatitis C virus antibodies or anti-human immunodeficiency virus 1 and 2 antibodies.
• •History of drug allergy diagnosed by a physician.
• •Use of tobacco within 30 days prior to the first study drug administration.
• •History of alcohol consumption exceeding 2 standard drinks per day on average.
• •Routine or chronic use of more than 0.5 grams of acetaminophen daily.
• •History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical research site or planned donation before 30 days has elapsed since intake of study drug.
• •Plasma or platelet donation within 7 days of dosing
• •Use of any investigational drug or device within 30 days of the first dose of study.